References
- Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of rare serious cutaneous adverse reactions. Results of the population based registry for erythema exsudativum multiforme with mucosal involvement (EEMM), Stevens-Johnson-syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). J Clin Epidemiol 1996; 49: 769–73
- Bastuji-Garin S, Rzany B, Stern R S., et al. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92–6
- Roujeau J-C, Kelly J P, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7
- Shapiro L E, Shear N H. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996; 15: 217–27
- Hertl M, Jugert F, Merk H F. CD8+ dermal T-cells from a sulfamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215–20
- Kelemen J J, Cioffi W G, McManus W F., et al. Burn center care for toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273–8
- Wolkenstein P, Latarjet J, Roujeau J-C, et al. Essai contrôlé du thalidomide dans la nécrolyse épidermîque toxique. Ann Dermatol Venereol 1997; 124(Suppl 1)S14